YOLFTbeta
Bright Minds Biosciences Inc

Bright Minds Biosciences Inc

DRUG · NASDAQ · Healthcare / Biotechnology

23.11USD+0.37 (+1.63%)

Price History

Full chart

Market Stats

Previous Close22.74
Open22.74
Day Range22.15 – 23.93
52-Week Range48.94 – 123.75
Volume118.57K
Market Cap525.04M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.85
Dividend Yield0.00%
Beta-0.11
50-Day Avg71.96
200-Day Avg77.53

About

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Ian McDonald
  • Employees26
  • Headquarters19 Vestry Street, New York, NY, United States, 10013, USA
  • Websitehttps://brightmindsbio.com

Leadership

  • Mr. Ian McDonaldCo-Founder, CEO, President & Director · b. 1988
  • Dr. Jan Torleif Pedersen M.Sc., Ph.D.Chief Science Officer & Director · b. 1965
  • Mr. Alex VasilkevichCOO & Senior Scientific Officer · b. 1989
  • Dr. Emer Leahy M.B.A., Ph.D.Consultant · b. 1967
  • Dr. Stephen D. Collins M.D., Ph.D.Chief Medical Officer · b. 1953

Financials

Income Statement

Currency: CAD2019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Total Revenue-000000
Cost of Revenue---6.04K72.45K-55.19K
Gross Profit----6.04K-72.45K--76.98K
Operating Expense---14.97M7.31M-13.86M
Operating Income-236.15K-469.36K-8.76M-14.98M-7.39M-2.82M-13.94M
EBITDA-78.72K-469.36K-8.76M-14.96M-7.30M-2.73M-12.15M
Net Income-236.15K-485.94K-8.52M-14.96M-7.37M-2.80M-12.23M
R&D126.03K354.85K6.31M12.18M5.00M1.18M11.08M
Interest Expense000222.78K19.75K-25.74K

Balance Sheet

Currency: CAD2019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Total Assets163.97K880.22K20.04M12.09M6.88M6.10M84.42M
Total Liabilities36.71K150.92K638.57K1.54M280.86K568.26K2.38M
Total Equity127.26K729.29K19.40M10.54M6.60M5.54M82.04M
Cash79.99K799.93K19.76M11.63M6.75M5.72M82.91M
Total Debt---139.91K73.55K118.96K125.78K
Net Debt-79.99K-799.93K-19.76M-11.49M-6.67M-5.60M-82.78M

Cash Flow

Currency: CAD2019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Operating Cash Flow-42.01K-288.39K-7.32M-13.59M-7.02M-1.85M-8.69M
Financing Cash Flow122.00K1.01M26.06M5.20M2.19M810.57K85.57M
Capital Expenditure0000500
Free Cash Flow-42.01K-288.39K-7.32M-13.59M-7.02M-1.85M-8.69M
FCF to OCF100.00%100.00%100.00%100.00%100.00%100.00%100.00%

Earnings

Report DateJun 17, 2021Aug 30, 2021Dec 29, 2021Feb 14, 2022May 15, 2022Aug 12, 2022Dec 28, 2022Feb 7, 2023May 15, 2023Aug 14, 2023Dec 29, 2023Feb 12, 2024May 14, 2024Aug 15, 2024Nov 27, 2024Feb 13, 2025May 15, 2025Aug 14, 2025Dec 23, 2025Feb 12, 2026May 19, 2026Aug 14, 2026
EPS Estimate------0.000.000.000.00-----0.60-0.50-0.39-0.88-1.00-1.18-1.26-1.39
EPS Actual-0.13-0.24-0.24-0.33-0.30-0.17-0.15-0.10-0.08-0.29-0.30-0.32-0.100.04-0.170.01-0.29-0.74-0.57-0.97-1.09-0.17
Surprise--------------71.67%102.00%25.64%15.91%42.86%17.80%13.49%87.77%
TimingAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours--After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap525.04M
Enterprise Value350.80M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book2.60
EPS-1.85
Book Value22.23
Revenue (TTM)0
Gross Profit (TTM)0
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-13.63%
Return on Assets-13.50%
Shares Outstanding9.81M
Shares Float6.69M
Beta-0.11
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 6 analystsTarget 167.20
  • Strong Buy
    4
  • Buy
    2

Ownership Breakdown

Institutions
94.88%
Insiders
11.94%
Retail / Other
0.00%

Top Institutional Holders

  • HHG PLC
    1.28M13.02%
  • Cormorant Asset Management, LLC
    1.06M10.74%
  • BlackRock Inc
    621.93K6.30%
  • Vivo Capital, LLC
    557.17K5.65%
  • BRAIDWELL LP
    539.71K5.47%
  • Vestal Point Capital LP
    492.32K4.99%
  • Driehaus Capital Management LLC
    432.51K4.38%
  • Adage Capital Partners Gp LLC
    335.00K3.40%
  • Balyasny Asset Management LLC
    297.16K3.01%
  • Deerfield Management Co
    283.00K2.87%
  • RA Capital Management, LLC
    265.00K2.69%
  • Parkman Healthcare Partners LLC
    205.05K2.08%
  • MPM Oncology Impact Management LP
    202.11K2.05%
  • Wellington Management Company LLP
    171.31K1.74%
  • Ikarian Capital, LLC
    166.65K1.69%
  • Morgan Stanley - Brokerage Accounts
    132.76K1.35%
  • Eventide Asset Management, LLC
    130.01K1.32%

Top Fund Holders

  • iShares Russell 2000 ETF
    191.51K1.94%
  • Janus Henderson Hrzn Biotec E2 USD
    166.05K1.68%
  • Eventide Healthcare & Life Sciences I
    130.01K1.32%

Stock Splits

  • Jul 14, 20231:5